Abstract #LBA7511

Results of a Randomized, Phase III Trial of nab-Paclitaxel and Carboplatin Compared With Cremophor-based

Paclitaxel and Carboplatin as First-line Therapy in Advanced Non-small Cell

Lung Cancer

Abstract #LBA7511

MA Socinski,1 I Bondarenko,2 NA Karaseva,3 AM Makhson,4 IO Vynnychenko,5 I Okamoto,6 J Hon,7 V Hirsh,8 P Bhar,9 J Iglesias9

1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , NC, USA; 2City Hosp #4, Dnepropetrovsk, Ukraine; 3City Oncology Center, St. Petersburg, Russia; 4City Oncology Hospital #62, Moscow,

Russia; 5Regional Oncology Center, Sumy, Ukraine; 6Kinki University School of Medicine, Osaka-Sayama, Japan; 7Clearview Cancer Inst Onc Specialties, P.C, Huntsville, AL, USA; 8McGill University, Montreal, Quebec, Canada;

9Abraxis BioScience, Los Angeles, CA

Study Rationale

Platinum-based doublets have reached a therapeutic plateau in advanced NSCLC

Paclitaxel plus carboplatin produces overall response rates of 15-25% (Kelly 2001; Sandler 2006; Schiller 2002) and survival outcomes comparable to all other doublets

The solvent polyoxyethylated castor oil (cremophor) may decrease efficacy and contribute to the toxicities observed with paclitaxel including hypersensitivity reactions and neuropathy

Nanoparticle albumin-bound (nab) paclitaxel has been shown to be more efficacious than solvent-based paclitaxel in MBC (Gradishar 2005)

Biologic Rationale for nab-P

nab-P leverages the gp60 / caveolin-1 / SPARC transcytosis pathway to establish a portal to the tumor microenvironment resulting in high intra-tumoral drug concentration (Desai 2008)

Overexpression of caveolin-1 and SPARC occurs in NSCLC and is associated with poor prognosis (Yoo, 2002; Chin 2005; Koukorakis, 2003)

nab-Paclitaxel With Carboplatin (nab-P/C) in Advanced NSCLC: A Dose-finding

Nonrandomized Phase II A 7 arm trial investigated the safety and efficacy of nab-P/C at

both weekly and q3w dosing schedules (Socinski, JTO 5:852-61, 2010)

Weekly nab-paclitaxel (100 mg/m2 d1, 8, 15) plus carbo AUC 6 q3w demonstrated optimal therapeutic index

• RR = 48%, median PFS = 6.2 months, median OS = 11.3 months

• Grade 3/4 toxicity: neutropenia 64%, neuropathy 8%, thrombocytopenia 20%, anemia 16%

Based on the phase II results, a phase III trial was designed to investigate the efficacy / safety of nab-P/C vs P/C as first-line therapy in advanced NSCLC

Phase III nab-P/C vs P/CStudy Design

Chemo-naivePS 0-1

Stage IIIb/IV NSCLC

N = 1,050

Stratification factors: Stage (IIIb vs IV) Age (<70 vs >70) Sex Histology (squamous vs nonsquamous) Geographic region

nab-Paclitaxel 100 mg/m2 d1,8,15Carboplatin AUC 6 d1

No Premedicationn = 525

1:1

Paclitaxel 200 mg/m2 d1Carboplatin AUC 6 d1

With Premedication of Dexamethasone +

Antihistaminesn = 525

Study Endpoints

Primary endpoint: Objective response rate by independent radiologic review

based on RECIST• complete + partial response (CR, PR)

Secondary endpoints: Progression-free and overall survival Disease control rate: CR + PR + stable disease (SD) ≥16

weeks Safety (NCI CTCAE v3)

Study Endpoints

Primary endpoint: Objective response rate by independent radiologic review

based on RECIST• complete + partial response (CR, PR)

Secondary endpoints: Progression-free and overall survival Disease control rate: CR + PR + stable disease (SD) ≥16

weeks Safety (NCI CTCAE v3)

Patient Eligibility

Major Inclusion Histologically/cytologically confirmed adult patients with stage IIIb/IV

NSCLC ECOG performance status of 0 or 1 Measurable disease by RECIST Adequate hematologic, hepatic, and renal function No prior treatment for metastatic disease (adjuvant therapy allowed if

it was >1 year prior to study entry)

Major Exclusion Active brain metastases (treated, controlled mets allowed) Baseline peripheral neuropathy > grade 2

Statistical ConsiderationsPrimary Endpoint

Objective response rate of P/C in ECOG 1594 = 17% Based on the activity of nab-P in MBC, a relative

improvement of ~40% for nab-P/C over P/C was assumed (corresponding to an ORR = 24%)

Based on this assumption, 525 patients on each arm provides 80% power with a two-sided Type I error of 0.049 to reject the null hypothesis

US12% (25 sites)

Russia 45% (29 sites)

Australia1%

(5 sites)

Japan14%

(21 sites)

Patient Accrual

Canada4% (6 sites) Ukraine

24% (16 sites)

Planned enrollment: from Dec 14 2007 to Aug 1, 2009Actual enrollment: from Dec 14 2007 to July 14, 2009Planned follow-up: 18 months# of patients enrolled: 1052# of patients evaluable for efficacy: 1052# of patients evaluable for toxicity: 1038

Results: Baseline Demographicsnab-P/C(n = 521)

P/C(n = 531)

All Patients(N = 1052)

Age, median (range) years 60 (28, 81) 60 (24, 84) 60 (24, 84)

<70 years, n (%) ≥70 years, n (%)

448 (86)73 (14)

449 (85)82 (15)

897 (85)155 (15)

Female, n (%) 129 (25) 134 (25) 263 (25)

ECOG, n (%)

0 133 (26) 113 (21) 246 (23)

1 385 (74) 416 (78) 801 (76)

Histology of Primary Diagnosis, n (%)*

Adenocarcinoma 254 (49) 264 (50) 518 (49)

Squamous Cell Carcinoma 228 (44) 221 (42) 449 (43)

Large Cell Carcinoma 9 (2) 13 (2) 22 (2)

Other 29 (6) 33 (6) 62 (6)

Stage at Current Diagnosis, n (%)*

Stage III 99 (19) 107 (20) 206 (20)

Stage IV 421 (81) 424 (80) 845 (80)

Prior Chemotherapy, n (%) 12 (2) 8 (2) 20 (2)

Smoking Status, n (%) 513 521 1034

Never Smoked 138 (27) 144 (28) 282 (27)

Smoked and Quit 165 (32) 146 (28) 311 (30)

Smoked and Still Smokes 210 (41) 231 (44) 441 (43)

* Data was missing for 1 pt at the time of this analysis

Dose Intensity and Administered Cycles

nab-P/C(n = 514)

P/C(n = 524)

Taxane Dose Intensity (mg/m2/wk)

Median (min, max) 83 (26.7, 102.9) 66 (32.9, 88.9)

Cycles Administered

Median (min, max) 6 (1, 17) 6 (1, 22)

There was no limitation on the # of cycles

Primary Endpoint ResultsObjective Responses – All Histologies

33%

25%

0%

10%

20%

30%

40%

IndependentRadiologic Review

nab-P/C

P/C

Response Ratio = 1.31(1.082 – 1.593)

P = 0.005

Pe

rce

nt

Re

sp

on

ses

33%

37%

25%

30%

0%

10%

20%

30%

40%

IndependentRadiologic Review

InvestigatorAssessment

nab-P/C

P/C

Response Ratio = 1.31(1.082 – 1.593)

P = 0.005

Response Ratio = 1.26(1.060 – 1.496)

P = 0.008

Pe

rce

nt

Re

sp

on

ses

Primary Endpoint ResultsObjective Responses – All Histologies

(n = 521)

(n = 531)

37%41%

29%

24%

0%

10%

20%

30%

40%

50%

IndependentRadiologic

Review

InvestigatorAssessment

nab-P/C

P/C

Pe

rce

nt

Re

sp

on

ses

* Not a pre-specified endpoint

Objective Responses by Histology*

Squamous

P < 0.001 P = 0.060

n = 228 n = 221

41%37%

26%

37%

24%

29%25%

30%

0%

10%

20%

30%

40%

50%

IndependentRadiologic

Review

InvestigatorAssessment

IndependentRadiologic

Review

InvestigatorAssessment

nab-P/C

P/C

Pe

rce

nt

Re

sp

on

ses

Objective Responses by Histology*

Squamous Nonsquamous

P < 0.001 P = 0.060 P = 0.808 P = 0.069

n = 228 n = 221 n = 292 n = 310

* Not a pre-specified endpoint

nab-P/C(n = 514)

P/C(n = 524)

Adverse Events, % Grade 3 Grade 4 Grade 3 Grade 4P-values for

grade 3/4

Hematologic

Neutropenia 33 12 33 23 0.009*

Thrombocytopenia 13 4 6 2 <0.001**

Anemia 22 5 6 <1 <0.001**

Febrile Neutropenia <1 <1 1 <1 NS

Nonhematologic

Fatigue 4 <1 6 <1 NS

Sensory Neuropathy 3 0 10 0 <0.001*

Anorexia 2 0 <1 0 NS

Nausea 1 0 <1 <1 NS

Myalgia <1 0 2 0 0.011*

Safety

No hypersensitivity reaction occurred in the nab-P/C arm without prophylactic premedication, while 3 occurred in the P/C arm (grade 1, 2, and 3, respectively).

* Favors nab-P/C; ** Favors P/C

nab-P/C(n = 514)

P/C(n = 524)

Adverse Events, % Grade 3 Grade 4 Grade 3 Grade 4P-values for

grade 3/4

Hematologic

Neutropenia 33 12 33 23 0.009*

Thrombocytopenia 13 4 6 2 <0.001**

Anemia 22 5 6 <1 <0.001**

Febrile Neutropenia <1 <1 1 <1 NS

Nonhematologic

Fatigue 4 <1 6 <1 NS

Sensory Neuropathy 3 0 10 0 <0.001*

Anorexia 2 0 <1 0 NS

Nausea 1 0 <1 <1 NS

Myalgia <1 0 2 0 0.011*

Safety

No hypersensitivity reaction occurred in the nab-P/C arm without prophylactic premedication, while 3 occurred in the P/C arm (grade 1, 2, and 3, respectively).

* Favors nab-P/C; ** Favors P/C

nab-P/C(n = 514)

P/C(n = 524)

Adverse Events, % Grade 3 Grade 4 Grade 3 Grade 4P-values for

grade 3/4

Hematologic

Neutropenia 33 12 33 23 0.009*

Thrombocytopenia 13 4 6 2 <0.001**

Anemia 22 5 6 <1 <0.001**

Febrile Neutropenia <1 <1 1 <1 NS

Nonhematologic

Fatigue 4 <1 6 <1 NS

Sensory Neuropathy 3 0 10 0 <0.001*

Anorexia 2 0 <1 0 NS

Nausea 1 0 <1 <1 NS

Myalgia <1 0 2 0 0.011*

Safety

No hypersensitivity reaction occurred in the nab-P/C arm without prophylactic premedication, while 3 occurred in the P/C arm (grade 1, 2, and 3, respectively).

* Favors nab-P/C; ** Favors P/C

Conclusions

In this phase III randomized trial, nab-P/C demonstrated a statistically significant higher response rate than P/C (33% vs 25 %, P < 0.001).

The response rate in the squamous cell subset was 41% in the nab-P/C arm vs 24% in the P/C arm (P < 0.001).

nab-P/C was well tolerated and associated with less sensory neuropathy, myalgia, and neutropenia than P/C.

nab-P/C was associated with more anemia and thrombocytopenia than P/C.

Progression-free survival analysis is planned for later this year.

Acknowledgments

We would like to thank all of the participating patients and their families, as well as the global network of investigators, research nurses, study coordinators, and operations staff.

Acknowledgments

We would like to thank all of the participating patients and their families, as well as the global network of investigators, research nurses, study coordinators, and operations staff.

Thank you